Carl Deselm is an Oncology physician affiliated with Washington University in St. Louis. OpenAlex indexes 128 publications with 2,456 citations (h-index 18); ClinicalTrials.gov lists 1 registered study matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
4921 Parkview Pl
Dept Radiation Oncology, Ll
Saint Louis, MO 631101032
Telephone
314-747-7236Provider last certified this registry record 11 Jan 2022.
Clinical trials
- Stereotactic Body Radiotherapy Plus FAK and RAF/MEK Inhibition in Advanced Pancreatic Adenocarcinoma
Sponsor: Washington University School of Medicine
- Total Neoadjuvant Therapy With Short Course Radiation Therapy in Gastric Cancer
Sponsor: Washington University School of Medicine
- MicroEnvironment Tumor Effects of Radiotherapy - Comprehensive Radiobiology Assessment TRial
Sponsor: Washington University School of Medicine
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Metabolism & gastrointestinal
100%Antidiarrheal microorganisms100%Creon100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
4 NIH research awards on record, funded 2009–2026 per NIH RePORTER. The latest:
- Harnessing TLR4 Signaling Pathways in CAR Dendritic Cells to Overcome Tumor Immune Tolerance
Washington University
FY2026$399,829R21CA313766
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Feasibility of Stereotactic Body Radiation Therapy for Pancreatic Tumors Abutting Organs at Risk Using Magnetic Resonance Guided Adaptive Radiation Therapy
International Journal of Radiation Oncology*Biology*Physics
2025 - Exploitable mechanisms of antibody and CAR mediated macrophage cytotoxicity
Nature Communications
2025 - Low-dose radiation as a preconditioning regimen for dendritic cell vaccines.
Journal of Clinical Oncology
2024
Similar KOLs
Other experts from the same institution or the same specialty.
Timothy Ley, MD
Washington University in St. Louis
David Gutmann, MD
Washington University in St. Louis
Randall Bateman, MD
Washington University in St. Louis
Victoria Fraser, MD
Washington University in St. Louis
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”